|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...112113114115116117118119120121122...156157» |
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment change: A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Oct 6, 2013
P3, N=38, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=61 --> 38
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed: A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Oct 6, 2013
P3, N=38, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=61 --> 38 Recruiting --> Active, not recruiting
- Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed: A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 6, 2013
P=N/A, N=50, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| BI 695500 (rituximab biosimilar) / Boehringer Ingelheim
New P3 trial: Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis (clinicaltrials.gov) - Oct 4, 2013
P3, N=250, Recruiting, Sponsor: Boehringer Ingelheim
- ||||| Ilaris (canakinumab) / Novartis
Enrollment change: ?-SPECIFIC 3: An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-na (clinicaltrials.gov) - Oct 4, 2013
P3, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=200 --> 300
- avdoralimab (IPH5401) / Innate
New P1 trial, PK/PD data: A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Oct 4, 2013
P1, N=26, Recruiting, Sponsor: Novo Nordisk A/S
- |||||| Ilaris (canakinumab) / Novartis
Enrollment open: ?-SPECIFIC 3: An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-na (clinicaltrials.gov) - Oct 4, 2013
P3, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
N=200 --> 300 Active, not recruiting --> Recruiting
- glatiramer acetate / Generic mfg.
Enrollment change: Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis (clinicaltrials.gov) - Oct 3, 2013
P=N/A, N=17, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Recruiting N=30 --> 17
- glatiramer acetate / Generic mfg.
Trial completion: Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis (clinicaltrials.gov) - Oct 3, 2013
P=N/A, N=17, Completed, Sponsor: University of California, San Francisco
N=30 --> 17 Active, not recruiting --> Completed
- Humira (adalimumab) / AbbVie
Biomarker, Enrollment change: Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA) (clinicaltrials.gov) - Sep 30, 2013
P4, N=69, Completed, Sponsor: University Hospital, Tours
Active, not recruiting --> Completed N=100 --> 69
- Humira (adalimumab) / AbbVie
Biomarker, Trial completion: Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA) (clinicaltrials.gov) - Sep 30, 2013
P4, N=69, Completed, Sponsor: University Hospital, Tours
N=100 --> 69 Recruiting --> Completed
- ||||| Mavenclad (cladribine) / EMD Serono
Trial initiation date: CLARITY: A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Sep 29, 2013
P3, N=1326, Completed, Sponsor: EMD Serono
Recruiting --> Completed Initiation date: Jan 2005 --> Apr 2005
- Clinical data, Adverse events: Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions (clinicaltrials.gov) - Sep 29, 2013
P=N/A, N=3000, Recruiting, Sponsor: Elliot Lander
- ||| Cervarix (recombinant human papillomavirus bivalent vaccine) / GSK, Japan Vaccine
Clinical: Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom (clinicaltrials.gov) - Sep 29, 2013
P=N/A, N=260000, Not yet recruiting, Sponsor: GlaxoSmithKline
- || Humira (adalimumab) / Eisai, AbbVie
New P3 trial: Impact of Adalimumab Therapy on Brachial Endothelial Function and Large Artery Stiffness in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 29, 2013
P3, N=60, Recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
- Enrollment closed: Adipose Tissue Function After Pancreas Transplantation (clinicaltrials.gov) - Sep 29, 2013
P=N/A, N=15, Active, not recruiting, Sponsor: The University of Texas, Galveston
Initiation date: Jan 2005 --> Apr 2005 Recruiting --> Active, not recruiting
- Enrollment change: Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 27, 2013
P=N/A, N=18, Recruiting, Sponsor: SetPoint Medical Corporation
Recruiting --> Active, not recruiting N=10 --> 18
- mycophenolate mofetil / Generic mfg.
Trial initiation date: Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis (clinicaltrials.gov) - Sep 26, 2013
P3, N=24, Completed, Sponsor: Chulalongkorn University
N=10 --> 18 Initiation date: Jun 2008 --> May 2009
- mycophenolate mofetil / Generic mfg.
Enrollment change: Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis (clinicaltrials.gov) - Sep 26, 2013
P3, N=24, Completed, Sponsor: Chulalongkorn University
Initiation date: Jun 2008 --> May 2009 N=30 --> 24
- |||| R 333 / Rigel
Trial completion: SKINDLE: Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions (clinicaltrials.gov) - Sep 26, 2013
P2, N=53, Completed, Sponsor: Rigel Pharmaceuticals
N=30 --> 24 Recruiting --> Completed
- mycophenolate mofetil / Generic mfg.
Trial completion: Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis (clinicaltrials.gov) - Sep 26, 2013
P3, N=24, Completed, Sponsor: Chulalongkorn University
Recruiting --> Completed Recruiting --> Completed
- || Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change, HEOR: RA-PROACTIVE: Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) Patients (clinicaltrials.gov) - Sep 25, 2013
P=N/A, N=145, Active, not recruiting, Sponsor: UCB, Inc.
Recruiting --> Completed N=187 --> 145
- ||| Cosentyx (secukinumab) / Novartis
Enrollment closed: Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate (clinicaltrials.gov) - Sep 25, 2013
P2, N=221, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=187 --> 145 Recruiting --> Active, not recruiting
- Orencia (abatacept) / BMS
Enrollment change: Islet Transplantation Using Abatacept (clinicaltrials.gov) - Sep 25, 2013
P2, N=5, Active, not recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting N=20 --> 5
- Enrollment change: Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression (clinicaltrials.gov) - Sep 25, 2013
P2, N=8, Active, not recruiting, Sponsor: Emory University
N=20 --> 5 N=20 --> 8
- | Trial completion: Randomized Trial to Assess Efficacy and Safety of Continuous Glucose Monitoring in Children 4-<10 Years With T1DM (clinicaltrials.gov) - Sep 25, 2013
P3, N=146, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
N=20 --> 8 Active, not recruiting --> Completed
- | Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment closed: A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Sep 24, 2013
P3, N=47, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- modafinil / Generic mfg.
Trial completion: Modafinil in Multiple Sclerosis (clinicaltrials.gov) - Sep 24, 2013
P=N/A, N=20, Completed, Sponsor: Kessler Foundation
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Actemra SC (tocilizumab SC) / Roche, Halozyme
New P3 trial: An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis (clinicaltrials.gov) - Sep 24, 2013
P3, N=50, Recruiting, Sponsor: Hoffmann-La Roche
- mycophenolate mofetil / Generic mfg.
Enrollment open: Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis (clinicaltrials.gov) - Sep 24, 2013
P=N/A, N=90, Recruiting, Sponsor: Ramathibodi Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF (clinicaltrials.gov) - Sep 24, 2013
P3, N=28, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- riluzole / Generic mfg.
Trial completion: Neuroprotection With Riluzole Patients With Early Multiple Sclerosis (clinicaltrials.gov) - Sep 23, 2013
P2, N=43, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Clinical: GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus (clinicaltrials.gov) - Sep 23, 2013
P=N/A, N=1800, Completed, Sponsor: Novo Nordisk
- | chloroquine phosphate / Generic mfg.
New P4 trial: CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS (clinicaltrials.gov) - Sep 23, 2013
P4, N=62, Active, not recruiting, Sponsor: University of Sao Paulo General Hospital
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial initiation date: NIMRA: Novel Imaging Markers for Rheumatoid Arthritis (clinicaltrials.gov) - Sep 22, 2013
P4, N=20, Active, not recruiting, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Initiation date: Feb 2013 --> Oct 2013
- || staphylococcal protein A (PRTX-100) / Protalex
Enrollment change, Combination therapy: SPARTA: Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis (clinicaltrials.gov) - Sep 22, 2013
P1, N=64, Active, not recruiting, Sponsor: Protalex, Inc.
Initiation date: Feb 2013 --> Oct 2013 N=52 --> 64
- Trial completion: Rule-Based Closed Loop System for Type 1 Diabetes Control (clinicaltrials.gov) - Sep 22, 2013
P=N/A, N=0, Completed, Sponsor: Corporacion Parc Tauli
N=52 --> 64 Active, not recruiting --> Completed
- Trial completion: Development and Evaluation of Modified Yoga in Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Sep 22, 2013
P=N/A, N=57, Completed, Sponsor: McGill University Health Center
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion: Closing the Loop in Youth With Type 1 Diabetes in the Home Setting (clinicaltrials.gov) - Sep 21, 2013
P2, N=17, Completed, Sponsor: University of Cambridge
Recruiting --> Completed Recruiting --> Completed
- New P4 trial, Combination therapy, MRI: The Effect of Corticotrophin (ACTH) in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients (clinicaltrials.gov) - Sep 19, 2013
P4, N=20, Recruiting, Sponsor: Gaylis, Norman B., M.D.
- ||||||| Rituxan (rituximab) / Roche
Trial completion: SUNRISE: A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate (clinicaltrials.gov) - Sep 19, 2013
P3, N=559, Completed, Sponsor: Genentech
Recruiting --> Completed Active, not recruiting --> Completed
- | Arzerra (ofatumumab) / Novartis, Genmab
Trial termination: Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403 (clinicaltrials.gov) - Sep 18, 2013
P2, N=124, Terminated, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Terminated; The clinical development of intravenously administered ofatumumab in RA will no longer be pursued, so this study was prematurely terminated by the Sponsor.
- Trial completion: Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis (clinicaltrials.gov) - Sep 17, 2013
P1/2, N=18, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Terminated; The clinical development of intravenously administered ofatumumab in RA will no longer be pursued, so this study was prematurely terminated by the Sponsor. Suspended --> Completed
- Biomarker, Enrollment closed: Lymphoscreen: Profiling of Original Cellular and Humoral Biomarkers of Type 1 Diabetes (clinicaltrials.gov) - Sep 17, 2013
P=N/A, N=120, Active, not recruiting, Sponsor: Nantes University Hospital
Suspended --> Completed Recruiting --> Active, not recruiting
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study (clinicaltrials.gov) - Sep 17, 2013
P3, N=6, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change: Mobile Communication Technology for Adolescents With Diabetes (clinicaltrials.gov) - Sep 16, 2013
P=N/A, N=105, Completed, Sponsor: Indiana University
Active, not recruiting --> Completed N=40 --> 105
- | Trial completion: Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia (clinicaltrials.gov) - Sep 16, 2013
P1, N=12, Completed, Sponsor: Animas Corporation
N=40 --> 105 Recruiting --> Completed
- | New P1 trial: NoSIRS: Effects of Transvenous Vagus Nerve Stimulation on Immune Response: a Pilot Study (clinicaltrials.gov) - Sep 15, 2013
P1, N=22, Completed, Sponsor: Medtronic Cardiac Rhythm Disease Management
- Zostavax (zoster vaccine live) / Merck (MSD)
Trial completion: Zostavax in Systemic Lupus Erythematosus (clinicaltrials.gov) - Sep 15, 2013
P1, N=20, Completed, Sponsor: Oklahoma Medical Research Foundation
Recruiting --> Completed Recruiting --> Completed
- || Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment closed: GO-NICE: A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554) (clinicaltrials.gov) - Sep 12, 2013
P=N/A, N=1500, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Recruiting --> Active, not recruiting